简介:【摘要】目的:分析0~6岁儿童保健的举措,分析具体的结果。方法:选择2017年01月-2018年12月我院接受的0-6岁的80例儿童为对象,随机实施分组,对照组40例不采用任何干预举措,观察组的40例实施的是保健干预指导,保健指导后对具体的数据分析,总结效果。结果:对比两组儿童的自身发育情况,观察组的PDI、MDI指标值高于对照组。观察组的疾病发生几率是5%,对照组是12.5%,观察组的疾病发生几率低于对照组,数据对比具备统计学意义(P<0.05)。结论:针对0-6岁的儿童实施保健干预指导,整体上有重要的作用,需要及时落实,确保儿童的身心健康发展。
简介:目的:探讨LEEP术(宫颈环形电切术)治疗宫颈疾病的手术指症,并发症及预防措施。方法:对我院的宫颈疾病患者200例使用LEEP刀治疗情况做一回顾性分析探讨其手术效果及其并发症。结果:手术成功率99%,并发症发生率15%,手术平均时间10分钟平均出血量20ml。结论:LEEP刀手术是一种安全,有效,快速,微创的治疗宫颈病变的方法。
简介:AbstractBackground:The elimination of Plasmodium vivax malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia. Several point-of-care devices have been developed to detect G6PD deficiency. The objective of the present study was to evaluate the performance of two of these devices against G6PD genotypes in Mauritania.Methods:Outpatients were screened for G6PD deficiency using CareStart™ rapid diagnostic test (RDT) and CareStart™ G6PD biosensor in Nouakchott, Mauritania, in 2019-2020. African-type and Mediterranean-type G6PD genotypes commonly observed in Africa were determined by polymerase chain reaction-restriction fragment length polymorphism and sequencing. Qualitative variables were compared using Fisher’s exact test.Results:Of 323 patients (74 males and 249 females), 5 males and 2 homozygous females had the African-type A-genotype: A-(202) in 3 males and 2 females and G6PD A-(968) in 2 males. Among heterozygous females, 13 carried G6PD A-(202), 12 G6PD A-(968), and 3 G6PD A-(542) variants. None had the Mediterranean-type G6PD genotype. Eight had a positive G6PD RDT result, including all 7 hemizygous males and homozygous females with A- or A-A- (0.12 to 2.34 IU/g haemoglobin, according to G6PD biosensor), but RDT performed poorly (sensitivity, 11.1% at the cutoff level of < 30%) and yielded many false negative tests. Thirty-seven (50.0%) males and 141 (56.6%) females were anaemic. The adjusted median values of G6PD activity were 5.72 and 5.34 IU/g haemoglobin in non-anaemic males (n = 35) and non-anaemic males and females (n = 130) with normal G6PD genotypes using G6PD biosensor, respectively. Based on the adjusted median of 5.34 IU/g haemoglobin, the performance of G6PD biosensor against genotyping was as follows: at 30% cut-off, the sensitivity and specificity were 85.7% and 91.7%, respectively, and at 80% cut-off, the sensitivity was 100% while the specificity was 64.9%.Conclusions:Although this pilot study supports the utility of biosensor to screen for G6PD deficiency in patients, further investigation in parallel with spectrophotometry is required to promote and validate a more extensive use of this point-of-care device in areas where P. vivax is highly prevalent in Mauritania.